A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| BMS-936559 | Anti-PD-L1 monoclonal antibody BMS-936559 binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. Synonyms: MDX1105; BMS936559; MDX 1105; BMS 936559; MDX-1105; BMS-936559; Anti PD L1; PD-L1 inhibitor -Bristol-Myers Squibb. |  |
| BMS-955176 | BMS-955176 is the second generation HIV-1 maturation inhibitor. Synonyms: BMS-955176 free base|BMS-955176|UNII-4CA9IAU7RJ|4CA9IAU7RJ|GSK3532795|1392312-45-6|1392312-45-6 (free base)|GSK-3532795|CHEMBL3827379|SCHEMBL12697862|BMS-955176 TFA|EX-A3677|BDBM50450015|BMS955176|DB15193|2097784-79-5|AC-36687|HY-112714|CS-0062829|4((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)3a-((2-(1,1-Dioxidothiomorpholino)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6. Grade: ≥98% (HPLC). CAS No. 1392312-45-6. Molecular formula: C42H62N2O4S. Mole weight: 691. | |
| BMS-955176 free base | GSK3532795, also known as BMS-955176, is a potent, orally active, second-generation HIV-1 maturation inhibitor (MI) that advanced through phase IIb clinical trials. GSK3532795 combines broad coverage of polymorphic viruses (EC50 <15 nM toward a panel of common polymorphisms representative of 96.5% HIV-1 subtype B virus) with a favorable pharmacokinetic profile in preclinical species. Uses: Designed for use in research and industrial production. Additional or Alternative Names: GSK3532795; GSK-3532795; GSK 3532795; BMS-955176; BMS 955176; BMS955176. Product Category: Inhibitors. Appearance: Solid powder. CAS No. 1392312-45-6. Molecular formula: C42H62N2O4S. Mole weight: 691.03. Purity:>98%. IUPACName: 4 - ((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR) - 3a-((2-(1,1-Dioxidothiomorpholino)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13boctadecahydro - 1H - cyclopenta[a]chrysen-9-yl)benzoic Acid. Canonical SMILES: O=C(O)C1=CC=C(C2=CC[C@@]3(C)[C@@](C2(C)C)([H])CC[C@@]4(C)[C@]5(C)CC[C@](CC[C@H]6C(C)=C)(NCCN(CC7)CCS7(=O)=O)[C@@]6([H])[C@@]5([H])CC[C@]34[H])C=C1. Product ID: ACM1392312456. Alfa Chemistry ISO 9001:2015 Certified. |  |
| BMS-955176 TFA | BMS-955176 TFA is the second generation HIV-1 maturation inhibitor. Synonyms: MS-955176 TFA. CAS No. 2097784-79-5. Molecular formula: C44H63F3N2O6S. Mole weight: 805.05. | |
| BMS-955829 | BMS-955829 shows excellent Metabotropic glutamate receptor 5 (mGluR5) binding affinity, low glutamate fold shift, and high selectivity for the mGluR5 subtype. BMS-955829 is a potent mGluR5 Positive allosteric modulator (PAM) (EC50 = 2.6 ± 1.0 nM; n=6), devoid of inherent mGluR5 agonist activity (EC50 > 30μM). It may become a new drug candidate for the treatment of schizophrenia. Uses: Schizophrenia. Synonyms: BMS-955829; BMS 955829; BMS955829. (4R,5R)-5-(2,5-difluorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one. Grade: 98%. CAS No. 1375751-08-8. Molecular formula: C22H14F2N2O2. Mole weight: 376.36. | |
| BMS 961 | BMS 961 is a potent and selective retinoic acid receptor gamma (RARγ) agonist with an IC50 value of 30 nM. Synonyms: BMS961; BMS-961; 3-Fluoro-4-[[2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)acetyl]amino]-benzoic acid; Benzoic acid, 3-fluoro-4-[[2-hydroxy-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)acetyl]amino]-. Grade: ≥97% by HPLC. CAS No. 185629-22-5. Molecular formula: C23H26FNO4. Mole weight: 399.45. | |
| BMS 961 | BMS 961. Group: Biochemicals. Grades: Purified. CAS No. 185629-22-5. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. |  Worldwide |
| BMS-978587 | BMS-978587 (IDO-IN-4) is an indoleamine 2,3-dioxygenase 1 ( IDO-1 ) inhibitor, extracted from patent WO2014150677A1, Compound example 1 enantiomer 1. Uses: Scientific research. Group: Signaling pathways. Alternative Names: IDO-IN-4. CAS No. 1629125-65-0. Pack Sizes: 10 mM * 1 mL; 2 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-18769. |  |
| BMS-983970 | BMS-983970 is an oral pan-Notch inhibitor for the treatment of cancer. Synonyms: BMS-983970; BMS 983970; BMS983970. Grade: >98%. CAS No. 1584713-87-0. Molecular formula: C26H26F4N4O3. Mole weight: 518.5. | |
| BMS-984923 | BMS-984923 is a potent mGluR5 silent allosteric modulator (SAM) with exquisite binding affinity (Ki = 0.6 nM). BMS-984923 exhibits good oral bioavailability and BBB penetration. BMS-984923 potently inhibits the PrPC-mGluR5 interaction and prevents pathological Aβo signaling without affecting physiological glutamate signaling. Synonyms: BMS984923; 2-Oxazolidinone, 5-(2-chlorophenyl)-4-(5-(2-phenylethynyl)-3-pyridinyl)-, (4R,5R)-. CAS No. 1375752-78-5. Molecular formula: C22H15ClN2O2. Mole weight: 374.82. | |
| BMS 986020 | BMS 986020 is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist with an IC50 value less than 300 nM for human LPA1 expressing CHO cells. It inhibits bile acid and phospholipid transporters with IC50s of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively. BMS 986020 is used for the treatment of idiopathic pulmonary fibrosis (IPF). Synonyms: BMS-986020; BMS986020. Grade: ≥98%. CAS No. 1257213-50-5. Molecular formula: C29H26N2O5. Mole weight: 482.5. | |
| BMS-986020 | BMS-986020 (AM152) is a high-affinity and selective lysophosphatidic acid receptor 1 (LPA1) antagonist[1]. BMS-986020 inhibits bile acid and phospholipid transporters with IC50s of 4.8 ?M, 6.2 ?M, and 7.5 ?M for BSEP, MRP4, and MDR3, respectively[2]. BMS-986020 has the potential for the treatment of idiopathic pulmonary fibrosis (IPF)[3]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: AM152. CAS No. 1257213-50-5. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100619. | |
| BMS-986020 sodium | BMS-986020 (AM152) sodium is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist[1]. BMS-986020 sodium inhibits bile acid and phospholipid transporters with IC50s of 4.8 ?M, 6.2 ?M, and 7.5 ?M for BSEP, MRP4, and MDR3, respectively[2]. BMS-986020 sodium has the potential for the treatment of idiopathic pulmonary fibrosis (IPF)[3]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: AM152 sodium. CAS No. 1380650-53-2. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-100619A. | |
| BMS-986020 sodium | BMS-986020 sodium is a high affinity antagonist of lysophosphatidic acid receptor 1 (LPA1) that inhibits bile acids and phospholipid transporters with IC50s of 4.8, 6.2 and 7.5 μM against BSEP, MRP4 and MDR3, respectively. It has the potential to treat idiopathic pulmonary fibrosis (IPF). Synonyms: Sodium 1-{4'-[3-methyl-4-({[(1R)-1-phenylethoxy]carbonyl}amino)-1,2-oxazol-5-yl]-4-biphenylyl}cyclopropanecarboxylate; Cyclopropanecarboxylic acid, 1-[4'-[3-methyl-4-[[[(1R)-1-phenylethoxy]carbonyl]amino]-5-isoxazolyl][1,1'-biphenyl]-4-yl]-, sodium salt (1:1); Sodium (R)-1-(4'-(3-methyl-4-(((1-phenylethoxy)carbonyl)amino)isoxazol-5-yl)-[1,1'-biphenyl]-4-yl)cyclopropane-1-carboxylate. Grade: ≥95%. CAS No. 1380650-53-2. Molecular formula: C29H25N2NaO5. Mole weight: 504.51. | |
| BMS-986094 | BMS-986094 (INX-08189) is a potent inhibitor of hepatitis C virus (HCV) replication, with an EC 50 of 35 nM at 24 h in Huh-7 cells. BMS-986094 is a phosphoramidate proagent of 6-O-methyl-2-C-methyl guanosine. BMS-986094 can be used for the research of chronic HCV infection [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: INX-08189. CAS No. 1234490-83-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-13337. | |
| BMS-986120 | BMS-986120, an imidazoles derivative, has been found to be a PAR4 antagonist that could probably be effective against thrombus propagation and pathological vascular occlusion. It was just completed a Phase I trail in in Thrombosis. Synonyms: BMS-986120; BMS 986120; BMS986120; 4-(4-(((6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)benzofuran-4-yl)oxy)methyl)-5-methylthiazol-2-yl)morpholine. Grade: 98%. CAS No. 1478712-37-6. Molecular formula: C23H23N5O5S2. Mole weight: 513.59. | |
| BMS-986120 | BMS-986120 is a first-in-class oral and reversible protease-activated receptor 4 ( PAR4 ) antagonist, with IC 50 s of 9.5 nM and 2.1 nM in human and monkey blood, respectively. BMS-986120 has potent and selective antiplatelet effects [1] [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1478712-37-6. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19837. | |
| BMS-986121 | BMS-986121 is an allosteric modulator (PAM) of the μ opioid receptor extracted from patent WO2014107344. CAS No. 313671-26-0. Molecular formula: C15H9Cl2N3O2S. Mole weight: 366.22. | |
| BMS 986122 | BMS 986122 is a positive allosteric modulator of the μ-Opioid receptor. It significantly increases the inhibition of forskolin-stimulated adenylyl cyclase activity produced by an EC10 (30 pM) concentration of endomorphin-I in CHO-μ cells. BMS 986122 potentiates endomorphin 1-induced inhibition of forskolin-stimulated adenylyl cyclase activity in CHO cells expressing human recombinant μ-opioid receptors with EC50 of 8.9 μM. It also enhances [35S]GTPγ binding stimulated by the μ-opioid agonist DAMGO by 7- and 4.5-fold in C6μ glioma cell membranes. Synonyms: BMS-986122; BMS986122; 2-(3-bromo-4-methoxyphenyl)-3-[(4-chlorophenyl)sulfonyl]-thiazolidine. Grade: ≥98%. CAS No. 313669-88-4. Molecular formula: C16H15BrClNO3S2. Mole weight: 448.8. | |
| BMS-986122 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. |  |
| BMS-986124 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| BMS-986141 | BMS-986141 is a potential medication under the clinical trial that evaluates the pharmacokinetics of BMS-986141 in participants with hepatic impairment compared to healthy participants. Synonyms: Unii-W530irz40G. CAS No. 1478711-48-6. Molecular formula: C27H23N5O5S2. Mole weight: 561.6. | |
| BMS-986142 | Bruton's tyrosine kinase (BTK) is a nonreceptor tyrosine kinase. It is a member of the Tec family of kinases. BTK plays an essential role in B cell receptor (BCR)-mediated signaling as well as Fcγ receptor signaling in monocytes and Fcε receptor signaling. BMS-986142 is a potent, selective and reversible BTK inhibitor with IC50 of 0.5 nM. It potently inhibits BCR-stimulated expression of CD69 on B cells in human whole blood with IC50 of 90 nM. Synonyms: BMS-986142; BMS986142. Grade: ≥98%. CAS No. 1643368-58-4. Molecular formula: C32H30F2N4O4. Mole weight: 572.60. | |
| BMS-986143 | BMS-986143 is an orally active, reversible BTK inhibitor with an IC50 of 0.26 nM. BMS-986143 also inhibits TEC, BLK, BMX, TXK FGR, YES1 and ITK with IC50s of 3 nM, 5 nM, 7 nM, 10 nM, 15 nM, 19 nM and 21 nM, respectively. BMS-986143 can be used in the study of autoimmune diseases. Synonyms: 3-chloro-4-(3-(5-chloro-1,3-dioxo-1H-pyrido[1,2-c]pyrimidin-2(3H)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9H-carbazole-1-carboxamide; 9H-Carbazole-1-carboxamide, 3-chloro-4-[3-(5-chloro-1,3-dioxo-1H-pyrido[1,2-c]pyrimidin-2(3H)-yl)-2-methylphenyl]-7-(1-hydroxy-1-methylethyl)-. Grade: ≥98%. CAS No. 1643372-95-5. Molecular formula: C31H24Cl2N4O4. Mole weight: 587.45. | |
| BMS-986158 | BMS-986158 is a potent BET inhibitor with IC 50 s of 6.6 and 5?nM in NCI-H211 small cell lung cancer (SCLC) cells and MDA-MB231 triple negative breast cancer (TNBC) cells, respectively [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1800340-40-2. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg. Product ID: HY-101567. | |
| BMS-986158 | BMS-986158 is an inhibitor of the bromodomain and extra-terminal (BET) proteins with potential antineoplastic activity. Synonyms: 2-[3-(3,5-dimethyltriazol-4-yl)-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-7-yl]propan-2-ol; BMS-986158; BMS 986158; BMS986158. CAS No. 1800340-40-2. Molecular formula: C30H33N5O2. Mole weight: 495.62. | |
| BMS-986165 | BMS-986165 is a potent and selective TYK2 inhibitor that blocks signal transduction of IL-23, IL-12, and type I IFNs. It binds to the Tyk2 pseudokinase domain (Ki = 0.02 nM), and is highly selective against a panel of 265 kinases and pseudokinases. BMS-986165 is under a phase III clinical trial for the treatment of Psoriasis. Synonyms: Deucravacitinib; BMS 986165; BMS986165; Tyk2-IN-4; Sotyktu. Grade: 98%. CAS No. 1609392-27-9. Molecular formula: C20H19D3N8O3. Mole weight: 425.47. | |
| BMS-986176 | BMS-986176, also known as LX9211, is a highly selective, CNS penetrant, potent AAK1 inhibitor from a novel class of bi(hetero)aryl ethers. BMS-986176/LX9211 (34) showed excellent efficacy in two rodent neuropathic pain models and excellent central nervous system (CNS) penetration and target engagement at the spinal cord with an average brain to plasma ratio of 20 in rat. The compound exhibited favorable physicochemical and pharmacokinetic properties, had an acceptable preclinical toxicity profile, and was chosen for clinical trials. Uses: Designed for use in research and industrial production. Additional or Alternative Names: LX9211; LX-9211; LX 9211; BMS-986176; BMS 986176; BMS986176. Product Category: Inhibitors. Appearance: Solid powder. CAS No. 1815613-42-3. Molecular formula: C19H23F4N3O. Mole weight: 385.41. Purity: >98%. IUPACName: ( S)-1-((2',6-Bis(difluoromethyl)-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amin. Canonical SMILES: CC(C)C[C@@](N)(C)COC1=C(C(F)F)N=C(C2=CC(C(F)F)=NC=C2)C=C1. Product ID: ACM1815613423. Alfa Chemistry ISO 9001:2015 Certified. | |
| BMS 986187 | BMS 986187 is a potent and selective δ-opioid receptor positive allosteric modulator (EC50 = 30 nM) exhibiting 100-fold selectivity for δ over μ-opioid receptor. Synonyms: BMS 986187; BMS986187; BMS-986187; 3,4,5,6,7,9-Hexahydro-3,3,6,6-tetramethyl-9-[4-[(2-methylphenyl)methoxy]phenyl]-1H-xanthene-1,8(2H)-dione. Grade: ≥98% by HPLC. CAS No. 684238-37-7. Molecular formula: C31H34O4. Mole weight: 470.61. | |
| BMS-986187 | BMS-986187 is an δ-opioid receptor -selective positive allosteric modulator (PAM) with an EC 50 of 0.03 μM and a pK B of 6.02 (~1 μM). BMS-986187 has no observable PAM activity at the μ-receptor (EC 50 =3 μM) [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 684238-37-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-120613. | |
| BMS 986188 | BMS 986188 is a novel potent and selective positive allosteric modulator of the delta-opioid receptor. It is selective for δ- over μ-opioid receptors with EC50 of 10 μM in the presence of leu-enkephalin and the μ-opioid receptor agonist endomorphin 1, respectively. Synonyms: MS-986188; BMS 986188. Grade: ≥98%. CAS No. 1776115-10-6. Molecular formula: C30H31BrO4. Mole weight: 535.5. | |
| BMS-986189 | BMS-986189 is a macrocyclic peptide PD-1/PD-L1 interaction with an IC50 of 1.03 nM inhibitor. BMS-986189 can be used for cancer research, such as human lung carcinoma cells L2987[1][2]. Uses: Scientific research. Group: Peptides. CAS No. 1629665-96-8. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-P10375. | |
| BMS-986195 | BMS-986195 is a Bruton's tyrosine kinase (BTK) inhibitor with IC50 of 0.1 nM. Synonyms: Branebrutinib; BMS 986195; BMS986195. Grade: ≥98% by HPLC. CAS No. 1912445-55-6. Molecular formula: C20H23FN4O2. Mole weight: 370.42. | |
| BMS986195 R-isomer | An R isomer of BMS-986195, a potent and selective inhibitor of Bruton's tyrosine kinase (BTK). Synonyms: (R)-4-(3-(But-2-ynamido)piperidin-1-yl)-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; (R)-Branebrutinib; (R)-BMS-986195. CAS No. 1912445-70-5. Molecular formula: C20H23FN4O2. Mole weight: 370.42. | |
| BMS-986205 | BMS-986205 is a selective indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor. It is undergoing a phase I/II clinical trial for the bladder and cervical cancer therapy in combination with nivolumab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody. Uses: Drug combination with nivolumab. Synonyms: BMS-986205; BMS 986205; BMS986205; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide. CAS No. 1923833-60-6. Molecular formula: C24H24ClFN2O. Mole weight: 410.917. | |
| BMS-986224 | BMS-986224 is a potent, selective and orally active APJ receptor agonist (Kd = 0.3 nM). BMS-986224 exhibits similar receptor binding and signaling profile to (Pyr1) apelin-13. BMS-986224 has the potential for the research of heart failure[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2055200-88-7. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-139485. | |
| BMS-986235 | BMS-986235 (LAR-1219) is a selective, orally active formyl peptide receptor 2 (FPR2) agonist, with EC50s of 0.41 nM and 3.4 nM for hFPR2 and mFPR2, respectively. BMS-986235 has potential for the prevention of heart failure[1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: LAR-1219. CAS No. 2253947-47-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 250 mg; 500 mg; 1 g. Product ID: HY-131180. | |
| BMS-986242 | BMS-986242 is a potent and selective inhibitor of Indoleamine 2,3-dioxygenase 1 (IDO1), a heme-containing dioxygenase enzyme implicated in cancer immune response. BMS-986242 has been developed for the treatment of a variety of cancers including metastatic melanoma and renal cell carcinoma. Synonyms: BMS 986242; BMS986242. Grade: 98% by HPLC. CAS No. 1923844-48-7. Molecular formula: C24H24ClFN2O. Mole weight: 410.9. | |
| BMS-986278 | BMS-986278 is a potent antagonist of lysophosphatidic acid receptor 1 (LPA1), with a human LPA1 Kb of 6.9 nM. Synonyms: (1S,3S)-3-((2-Methyl-6-(1-methyl-5-(((methyl(propyl)carbamoyl)oxy)methyl)-1H-1,2,3-triazol-4-yl)pyridin-3-yl)oxy)cyclohexane-1-carboxylic acid; Cyclohexanecarboxylic acid, 3-((2-methyl-6-(1-methyl-5-((((methylpropylamino)carbonyl)oxy)methyl)-1H-1,2,3-triazol-4-yl)-3-pyridinyl)oxy)-, (1S,3S)-. Grade: ≥95%. CAS No. 2170126-74-4. Molecular formula: C22H31N5O5. Mole weight: 445.51. | |
| BMS-986278 | BMS-986278 is a potent and orally active lysophosphatidic acid receptor 1 (LPA1) antagonist, with K b s of 6.9 nM and 4.0 nM for human and mouse LPA1, respectively. BMS-986278 can be used for the research of pulmonary fibrotic diseases [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2170126-74-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-139853. | |
| BMS-986299 | BMS-986299 (compound 112) is a first-in-class NLRP3 inflammasome agonist with an EC 50 of 1.28 μM. (patent WO2018152396A1). Uses: Scientific research. Group: Signaling pathways. CAS No. 2242952-69-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-139396. | |
| BMS-986299 | BMS-986299 is a first-in-class NLRP3 inflammasome agonist with EC50 of 1.28 μM. BMS-986299 is usdergoing a clinical trial alone and in combination with Nivolumab and Ipilimumab for the treatment of advanced solid tumors. Synonyms: BMS 986299; BMS986299. CAS No. 2242952-69-6. Molecular formula: C18H19N7O. Mole weight: 349.39. | |
| BMS-986365 | BMS-986365 (CC-94676) is an orally active and selective targeted androgen receptor ( AR ) PROTAC degrader, capable of inducing cereblon (CRBN) E3 ligase-dependent ubiquitination and degradation of the androgen receptor ( AR ), as well as various AR mutants. BMS-986365 shows significant in vivo potency, degrading AR , inhibiting AR signaling, and restricting tumor growth in animal models of advanced prostate cancer. (Blue: HY-W247437; Black: linker (HY-W126831); Pink: HY-168697) [1] [2] [3] [4] [5]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: CC-94676. CAS No. 2446928-30-7. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-158101. | |
| BMS-986397 | BMS-986397. Uses: Scientific research. Group: Signaling pathways. CAS No. 2564486-44-6. Pack Sizes: 5 mg; 10 mg; 25 mg. Product ID: HY-159646. | |
| BMS CCR2 22 | BMS CCR2 22 is a potent CCR2 antagonist. Synonyms: N-[2-[[2-[(4-methylsulfanylbenzoyl)amino]cyclohexyl]amino]-2-oxoethyl]-2-(propan-2-ylcarbamoylamino)-5-(trifluoromethyl)benzamide. CAS No. 445479-97-0. Molecular formula: C28H34F3N5O4S. Mole weight: 593.66. | |
| BMS CCR2 22 | BMS CCR2 22. Group: Biochemicals. Grades: Purified. CAS No. 445479-97-0. Pack Sizes: 1mg, 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| BMS-P5 | BMS-P5 is a selective and orally active peptidylarginine deiminase 4 (PAD4) inhibitor with an IC50 of 98 nM. BMS-P5 shows selective for PAD4 over PAD1, PAD2, and PAD3. BMS-P5 blocks multiple myeloma (MM)-induced neutrophil extracellular trap (NET) formation and delays progression of MM in a syngeneic mouse model[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1549811-36-0. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-137655. | |
| BMS-P5 | BMS-P5 is a novel peptidylarginine deiminase 4 (PAD4) inhibitor with pIC50 values in the range of 5-7.5. BMS-P5 blocks MM-induced NET formation and delays progression of MM in a syngeneic mouse model. Synonyms: BM P5; BMSP5; BMSP-5; BMSP 5; BMS-P5 HCl. CAS No. 1549811-36-0. Molecular formula: C27H33ClN6O2. Mole weight: 509.04. | |
| BMS-P5 free base | BMS-P5 is a novel peptidylarginine deiminase 4 (PAD4) inhibitor with pIC50 values in the range of 5-7.5. BMS-P5 blocks MM-induced NET formation and delays progression of MM in a syngeneic mouse model. Synonyms: [(2S,5R)-5-amino-2-methyl-1-piperidinyl][2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-methanone. Grade: 99%. CAS No. 1550371-22-6. Molecular formula: C27H32N6O2. Mole weight: 472.59. | |
| BMSpep-57 | BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs[1]. Uses: Scientific research. Group: Peptides. CAS No. 1629655-80-6. Pack Sizes: 1 mg; 5 mg. Product ID: HY-P3143. | |
| BMSpep-57 | BMSpep-57 is a potent and competitive PD-1/PD-L1 interaction macrocyclic peptide inhibitor. Synonyms: BMSpep-57; SCHEMBL17810340; HY-P3143; AKOS040756947; 1629655-80-6; CS-0149181. CAS No. 1629655-80-6. Molecular formula: C89H126N24O19S. Mole weight: 1868.16. | |
| BMT-1438 | BMT-1438 is a selective inhibitor of Janus kinase (JAK) family with less side effcts which is potentially used for the treatment of rheumatoid arthritis and other autoimmune diseases. It has a preference for JAK1 and JAK3. BMT-1438 showed excellent effect both in vitro and in a collagen-induced arthritis mouse model. Uses: The potential treatment of rheumatoid arthritis and other autoimmune diseases. Synonyms: BMT-1438; BMT 1438; BMT1438. | |
| BMT-145027 | BMT-145027 is a potent mGluR5 PAM without inherent agonist activity with an EC50 of 47 nM. BMT-145027 is a non-MPEP site PAM to demonstrate in vivo efficacy. Synonyms: BMT-145027; BMT 145027; BMT145027; 3-[4-chloro-3-(trifluoromethyl)phenyl]-4-cyclopropyl-6-phenyl-2H-pyrazolo[3,4-b]pyridine-5-carbonitrile. CAS No. 2018282-44-3. Molecular formula: C23H14ClF3N4. Mole weight: 438.83. | |
| Bmt I | One unit of the enzyme is the amount required to hydrolyze 1 μg of Lambda DNA (Hind III-digest) in 1 hour at 37°C in a total reaction volume of 50 μl. Applications: After 20-fold overdigestion with enzyme about 95% of the dna fragments can be ligated and recut. Group: Restriction Enzymes. Purity: 1000U; 5000U. GCTAG↑C C↓GATCG. Activity: 20000u.a./ml. Appearance: 10 X SE-buffer W. Storage: -20°C. Form: Liquid. Source: An E.coli strain that carries the cloned Bmt I gene from Bacillus megaterium S2. Pack: 10 mM Tris-HCl (pH 7.5); 200 mM NaCl; 0.1 mM EDTA; 1 mM DTT; 200 μg/ml BSA; 50% glycerol. Cat No: ET-1036RE. |  |
| Bmu I | One unit of the enzyme is the amount required to hydrolyze 1 μg of Lambda DNA (HindIII-digest) in 1 hour at 37°C in a total reaction volume of 50 μl. Applications: After 2-fold overdigestion with enzyme about 75% of the dna fragments can be ligated and 95% may be recut. Group: Restriction Enzymes. Purity: 50U; 250U. ACTGGG(N)5↑ TGACCC(N)4&darr. Activity: 500-1000u.a./ml. Appearance: 10 X SE-buffer Y. Storage: -20°C. Form: Liquid. Source: Bacillus megaterium S87. Pack: 10 mM Tris-HCl (pH 7.5); 250 mM NaCl; 0.1 mM EDTA; 7 mM 2-mercaptoethanol; 50% glycerol. Cat No: ET-1037RE. | |
| BMVC | BMVC is a potent G-quadruplex (G4) stabilizer and a selective telomerase inhibitor with an IC 50 of ~0.2 μM. BMVC inhibits Taq DNA polymerase with an IC 50 of ~2.5 μM. BMVC increases the melting temperature of G4 structure of telomere and accelerates telomere length shortening. Anticancer activities [1] [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 627810-06-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-135775. | |
| BMVC | BMVC is the first fluorescent probe designed to detect G-quadruplexes (G4s) in vivo. BMVC is a potent G-quadruplex (G4) stabilizer and a selective telomerase inhibitor. Grade: 98%. CAS No. 627810-06-4. Molecular formula: C28H25I2N3. Mole weight: 657.33. | |
| BMVC2 | BMVC2, a bisubstituted carbazole derivative of BMVC, is a G-quadruplex (G4) stabilizer. Synonyms: o-BMVC; 2,2'-((9H-Carbazole-3,6-diyl)bis(ethene-2,1-diyl))bis(1-methylpyridin-1-ium) iodide; 2,2'-[9H-Carbazole-3,6-diyldi(E)-2,1-ethenediyl]bis(1-methylpyridinium) diiodide. Grade: ≥95%. CAS No. 850559-51-2. Molecular formula: C28H25I2N3. Mole weight: 657.33. | |
| BMV Gag-(7-25) | It is a cell penetrating peptide. Synonyms: H-Lys-Met-Thr-Arg-Ala-Gln-Arg-Arg-Ala-Ala-Ala-Arg-Arg-Asn-Arg-Trp-Thr-Ala-Arg-OH; L-lysyl-L-methionyl-L-threonyl-L-arginyl-L-alanyl-L-glutaminyl-L-arginyl-L-arginyl-L-alanyl-L-alanyl-L-alanyl-L-arginyl-L-arginyl-L-asparagyl-L-arginyl-L-tryptophyl-L-threonyl-L-alanyl-L-arginine. Grade: ≥95%. Molecular formula: C96H170N44O24S. Mole weight: 2356.76. | |
| BMX, active, GST tagged human | recombinant, expressed in baculovirus infected Sf9 cells, ?70% (SDS-PAGE), buffered aqueous glycerol solution. Group: Fluorescence/luminescence spectroscopy. | |
| Bmx Active human | recombinant, expressed in E. coli, ?85% (SDS-PAGE), buffered aqueous glycerol solution. Group: Fluorescence/luminescence spectroscopy. | |
| BMX-IN-1 | A cell-permeable tricyclic quinoline-acrylamide compound that potently inhibits BMX and BTK kinase activity (IC50 = 8 and 10.4nM, respectively) by covalently targeting ATP-binding site cysteine, while being less potent against TEC family kinases TEC, JAK3, BLK with the same conserved cysteine (IC50 = 175, 377, and 653nM, respectively). Only PI 3-K gamma/PIK3CG, SBK1, PIP5K2C (by ≥94% at 1uM), and TXK (by 75% at 1uM) are significantly inhibited by BMX-IN-1 in a selectivity profiling against 437 other kinase constructs. Potently inhibits the proliferation of TEL-BMX transformed Ba/F3 Ba/F3 (GI50 = 25nM), while being much less effective against TEL-BLK, TEL-JAK1, TEL-JAK2, TEL-JAK3, or TEL-TYK2E957D transformed Ba/F3 (GI50 = ≥3.64uM) or a panel of 5 prostate cancer cell lines (GI50 ≥2.46uM). Group: Biochemicals. Alternative Names: N- (2-Methyl-5- (9- (4- (methylsulfonamido) phenyl) -2-oxobenzo[h][1, 6]naphthyridin-1 (2H) -yl) phenyl) acrylamide, BMX/BTK Inhibitor, Bruton's Tyrosine Kinase Inhibitor IV, BLK Inhibitor I, BMX Inhibitor I, JAK3 Inhibitor XIII, PI 3-K Inhibitor XX, PIP5K2C Inhibitor I, SBK1 Inhibitor I, TEC Inhibitor I, TXK Inhibitor I. Grades: Highly Purified. CAS No. 1431525-23-4. Pack Sizes: 10mg. Molecular Formula: C??H??N?O?S. US Biological Life Sciences. | Worldwide |
| BMX-IN-1 | BMX-IN-1 selectively and irreversibly inhibits BMX (IC50=8nM) that is significant for ischemia-mediated arteriogenesis and lymphangiogenesis regulation. It also inhibits the proliferation of RV-1 (GI50s=2.54μM), DU-145 (GI50s=4.38μM), PC-3 (GI50s=5.37nM). Synonyms: N-[5-[9-[4-(methanesulfonamido)phenyl]-2-oxobenzo[h][1,6]naphthyridin-1-yl]-2-methylphenyl]prop-2-enamideBMX-IN-1; BMX-IN1; BMX-IN 1.1431525-23-3GTPL9269SCHEMBL17052523BDBM102620CS-1295; HY-80002; W-6056; CS 1295; HY 80002; W 6056; CS1295; HY80002; W6056Example 1-14 [ WO2014063054]N-[5-[9-[4-(methanesulfonamido)phenyl]. CAS No. 1431525-23-3. Molecular formula: C29H24N4O4S. Mole weight: 524.59. | |
| BMX-IN-1 | BMX-IN-1 is a selective irreversible BMX inhibitor for prostate cancer. BMX-IN-1 can covalently modifies Cys496. BMX-IN-1 inhibits the proliferation of Tel-BMX-transformed Ba/F3 cells at two digit nanomolar concentrations but requires single digit micromolar concentrations to inhibit the proliferation of prostate cancer cell lines. MK2206, is able to potentiate BMX inhibitor's antiproliferation efficacy against prostate cancer cells. Uses: Designed for use in research and industrial production. Additional or Alternative Names: BMX-IN-1; BMX-IN1; BMX-IN 1. Product Category: Inhibitors. Appearance: Solid powder. CAS No. 1431525-23-3. Molecular formula: C29H24N4O4S. Mole weight: 524.6. Purity: >98%. IUPACName: N-[5-[9-[4-(methanesulfonamido)phenyl]-2-oxobenzo[h][1,6]naphthyridin-1-yl]-2-methylphenyl]prop-2-enamide. Canonical SMILES: C=CC(NC1=CC(N2C(C=CC3=C2C4=CC(C5=CC=C(NS(=O)(C)=O)C=C5)=CC=C4N=C3)=O)=CC=C1C)=O. Product ID: ACM1431525233. Alfa Chemistry ISO 9001:2015 Certified. | |
| BMY 14802 | BMY 14802 is a sigma-1 receptor ( σ1R ) antagonist, as well as an agonist at serotonin (5-HT) 1A and adrenergic alpha-1 receptors. BMY 14802 inhibits abnormal involuntary movement (AIM) in rat Parkinson's disease (PD) model, with down-regulating the expression of AIM [1] [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 105565-56-8. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-153091. | |
| BMY-14802 | ?97% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| BMY 14802 hydrochloride | BMY 14802 hydrochloride is a potent sigma receptor antagonist (IC50 = 112 nM) with weak affinity for 5-HT1A and α1 receptors. BMY 14802 is potentially used as an atypical antipsychotic agent for schizophrenia treatment. Uses: Potential atypical antipsychotic agent. Synonyms: BMY 14802 hydrochloride; BMS-181100 hydrochloride; BMY14802 hydrochloride; BMS181100 hydrochloride; BMY-14802 hydrochloride; BMS 181100 hydrochloride; BMY 14802 HCl; α-(4-Fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol hydrochloride. Grade: ≥98% by HPLC. CAS No. 105565-55-7. Molecular formula: C18H22F2N4O.HCl. Mole weight: 384.86. | |
| BMY-14802 hydrochloride | BMY-14802 hydrochloride (BMY-14802-1) is a selective and orally active sigma receptor antagonist with an IC 50 of 112 nM. BMY-14802 hydrochloride is also a 5-HT1A and adrenergic α1 receptors agonist. BMY-14802 hydrochloride has antipsychotic effects [1] [2] [3]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: BMY-14802-1; BMS 181100 hydrochloride. CAS No. 105565-55-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-108509. | |
| BMY-25271 | BMY-25271 is an antagonist of histamine H2 receptor. Synonyms: N-[2-[[[5-[(Dimethylamino)methyl]furan-2-yl]methyl]thio]ethyl]-1,2,5-thiadiazole-3,4-diamine 1-oxide; 1,2,5-Thiadiazole-3,4-diamine, N3-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-, 1-oxide. Grade: ≥95%. CAS No. 78441-82-4. Molecular formula: C12H19N5O2S2. Mole weight: 329.44. | |
| BMY-28160 | BMY-28160 is an ester peptide antibiotic produced by Bacillus circulans H913-B4. It has anti-gram-positive bacteria, negative bacteria, anaerobic bacteria and fungi activity. Synonyms: Polypeptin A, 2-L-valine-9-L-serine-. CAS No. 94593-78-9. Molecular formula: C53H90N12O12. Mole weight: 1087.35. | |
Our database is helping our users find suppliers everyday.
